Safety Information

Français

FR

 

Safety Information

Indication and clinical use:

TRINTELLIX (vortioxetine) is indicated for the treatment of MDD (Major Depressive Disorder) in adults.

Efficacy in providing symptomatic relief of MDD demonstrated in trials of up to 8 weeks’ duration; efficacy in maintaining an antidepressant response demonstrated for up to 24 weeks. 

Physicians who elect to use TRINTELLIX for extended periods should periodically re-evaluate the usefulness of the drug for individual patients.

The lowest effective dose of 5 mg/day should always be used as the starting dose in elderly patients (≥65 years of age).

Not indicated in pediatric patients.

Contraindication:

  • Combined use with monoamine oxidase inhibitors (MAOIs)

Most serious warnings and precautions:

  • Increased risk of self-harm, harm to others, suicidal thinking and behaviour: Closely monitor for clinical worsening and for emergence of agitation type and/or suicidal thoughts and behaviours. 

Other relevant warnings and precautions:

  • Potential for abuse
  • Discontinuation symptoms
  • Caution when driving or operating machinery
  • Abnormal bleeding
  • Potential for increased risk of postpartum hemorrhage
  • Caution in moderate or severe hepatic impairment 
  • Bone fracture risk
  • Caution in patients who have a history of seizures or in patients with unstable epilepsy
  • Serotonin toxicity/neuroleptic malignant syndrome
  • Cognitive and motor disturbances
  • Angle-closure glaucoma
  • Caution in patients with a history of mania/hypomania and discontinue use in any patient entering a manic phase
  • Aggression/agitation
  • Caution with concurrent use of electroconvulsive therapy (ECT)
  • Hyponatremia
  • Caution in patients with severe renal insufficiency 
  • Long-lasting sexual dysfunction
  • Not recommended during breastfeeding 
  • Dosage adjustment in elderly patients

For more information:

Consult the TRINTELLIX Product Monograph for important information about contraindications, warnings, precautions, adverse reactions, interactions, dosing instructions and conditions of clinical use not discussed in this piece.

The Product Monograph is also available by calling 1-800-586-2325.

Reference: TRINTELLIX Product Monograph. Lundbeck Canada Inc., May 27, 2024.

Canada Map Illustration and Trintellix female patient
Ontario British Columbia Alberta Manitoba New Brunswick Nova Scotia Prince Edward Island Quebec Saskatchewan Newfoundland and Labrador Yukon Nunavut NIHB Veteran Affairs
Find coverage

Need samples or more information about TRINTELLIX?

CONNECT WITH US

* Not available in Quebec
† TRINTELLIX is eligible for reimbursement by Non-Insured Health Benefits, Veteran Affairs Canada and Correctional Service Canada, and for formulary coverage in the following provinces and territories: Quebec, Ontario, Alberta, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Northwest Territories, Yukon and British Columbia (special authorization). Refer to provincial formularies for more information.

Reference: 1. Data on file: TRINTELLIX Coverage Canada. Lundbeck. December 2021.

Arrow pointing upward